Welcome to our dedicated page for ALNA news (Ticker: ALNA), a resource for investors and traders seeking the latest updates and insights on ALNA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALNA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALNA's position in the market.
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) announced its participation in H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13th to 15th, 2021. CEO Louis Brenner will join a pre-recorded fireside chat available on demand starting at 7:00 a.m. ET on September 13th. This discussion will focus on Allena's innovative oral biologic platform and their lead product candidate, reloxaliase, which is in Phase 3 clinical trials for enteric hyperoxaluria. Investors can access the webcast and schedule one-on-one meetings for deeper insights.
Allena Pharmaceuticals (NASDAQ: ALNA) reported its Q2 2021 results, revealing a net loss of $14.0 million compared to $7.0 million in Q2 2020. Research and development expenses rose to $10.1 million, up from $3.8 million year-over-year, as drug trials progress. The company completed a registered direct offering in July, raising $28.0 million. ALLN-346 has entered Phase 2a trials for gout and chronic kidney disease, with initial results expected in Q4 2021. Interim analysis for the Phase 3 URIROX-2 trial is now scheduled for Q1 2022, adapting to lower enrollment rates due to COVID-19.
Allena Pharmaceuticals (NASDAQ: ALNA) will participate in the 12th Annual Wedbush PacGrow Healthcare Conference from August 10-11, 2021. Louis Brenner, M.D., CEO, will join the Casino Re-nal Part 2 - Cysts and Stones panel on August 11 at 4:05 pm ET. Management will also hold 1x1 meetings during the conference. Allena focuses on developing oral enzyme therapeutics for rare metabolic and kidney disorders. Its lead product, reloxaliase, is in a pivotal Phase 3 clinical program for enteric hyperoxaluria, while ALLN-346 targets hyperuricemia in gout and chronic kidney disease.
Allena Pharmaceuticals (NASDAQ:ALNA) announced the granting of inducement awards to two new employees as a material inducement for their employment. On August 2, 2021, the employees received stock options to purchase 28,000 shares at an exercise price of $0.95 per share, reflecting the closing price at grant. The options vest over four years, with terms outlined in Allena’s 2021 Inducement Plan. Allena focuses on developing first-in-class oral enzyme therapeutics for rare metabolic and kidney disorders, with its lead candidate reloxaliase currently in a pivotal Phase 3 clinical program.
Allena Pharmaceuticals (NASDAQ: ALNA) announced a registered direct offering, selling 21,357,744 shares of common stock at $1.311 each and warrants for an additional 10,678,872 shares. The offering is expected to close around July 16, 2021, with proceeds estimated at $28 million for working capital and corporate purposes. H.C. Wainwright & Co. is the placement agent. The warrants have a five-year term and an exercise price of $1.25. Allena's financial struggles raise doubts about its ability to continue as a going concern without further capital.
Allena Pharmaceuticals (NASDAQ: ALNA) provided updates on its clinical trials for ALLN-346 and reloxaliase. The Phase 1b study for ALLN-346 concluded with no safety concerns, paving the way for two Phase 2a studies set for Q3 2021, with results anticipated in Q4 2021. Meanwhile, the URIROX-2 Phase 3 trial for reloxaliase is progressing, with a revised interim analysis planned for Q1 2022 due to COVID-19-related enrollment delays. Both drugs target severe metabolic and kidney disorders, addressing significant unmet needs in patients.
Allena Pharmaceuticals (NASDAQ: ALNA) announced that Dr. Louis Brenner, CEO, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, from 5:00 to 5:25 pm ET. The company will also hold one-on-one meetings on July 13-14, 2021. Allena is focused on developing oral enzyme therapeutics for rare metabolic and kidney disorders, with its lead candidate, reloxaliase, currently in a Phase 3 clinical trial for enteric hyperoxaluria. A replay of the webcast will be available on Allena's website for 90 days.
Allena Pharmaceuticals (NASDAQ: ALNA) announced the granting of inducement awards to two new employees as part of their employment agreements. On July 6, 2021, the employees were awarded stock options totaling 70,000 shares with an exercise price of $1.27 per share. The stock options vest over four years, reflecting the company’s commitment to attract talent in its pursuit of developing first-in-class oral enzyme therapeutics for rare metabolic and kidney disorders. Notably, Allena's lead candidate, reloxaliase, is in a pivotal Phase 3 clinical program.
Allena Pharmaceuticals (NASDAQ:ALNA) announced the granting of stock options to a new employee as an inducement for employment. On June 7, 2021, the company awarded stock options to purchase 55,000 shares at an exercise price of $1.20 per share, aligning with the closing trading price. Vesting occurs over four years, with 25% vested after one year and monthly thereafter. The options have a 10-year term. Allena focuses on developing oral enzyme therapeutics for rare metabolic and kidney disorders, with its lead candidate, reloxaliase, in Phase 3 trials.
Allena Pharmaceuticals (NASDAQ: ALNA) will host a KOL webinar on June 16, 2021, at 12:00 pm EDT, focusing on ALLN-346, an oral biologic in Phase 1 development for gout in chronic kidney disease (CKD). The session features Dr. Robert Terkeltaub from UC San Diego, addressing current treatment challenges. Allena will provide updates on its clinical programs, including a Phase 1 study and plans for a Phase 2a trial targeting hyperuricemia. This webinar aims to shed light on Allena's innovative therapeutics designed for rare metabolic and kidney disorders.
FAQ
What is the market cap of ALNA (ALNA)?
